Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.

about

The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis.Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability.Evaluating Risk Tolerance from a Systematic Review of Preferences: The Case of Patients with Psoriasis.

P2860

Q38707588-357BEEDC-5C6A-4B8A-ABEB-9BFA04B984BF Q42646805-4FB5934D-CE44-4709-AE76-DD50247FE30F Q47733253-AA8211E0-7781-41B8-AD44-3486F8C44D7D

P2860

Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.

Item

http://www.wikidata.org/entity/Q35860158

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Patient Preferences for Biolog ...... y for Cardiovascular Patients.

@ast

Patient Preferences for Biolog ...... y for Cardiovascular Patients.

@en

type

Item

label

Patient Preferences for Biolog ...... y for Cardiovascular Patients.

@ast

Patient Preferences for Biolog ...... y for Cardiovascular Patients.

@en

prefLabel

Patient Preferences for Biolog ...... y for Cardiovascular Patients.

@ast

Patient Preferences for Biolog ...... y for Cardiovascular Patients.

@en

P1476

Patient Preferences for Biolog ...... y for Cardiovascular Patients.

@en

P2093

Astrid Schmieder

http://www.w3.org/2001/XMLSchema#string

Christian Kromer

http://www.w3.org/2001/XMLSchema#string

Diana Sonntag

http://www.w3.org/2001/XMLSchema#string

Marthe-Lisa Schaarschmidt

http://www.w3.org/2001/XMLSchema#string

Raphael Herr

http://www.w3.org/2001/XMLSchema#string

Sergij Goerdt

http://www.w3.org/2001/XMLSchema#string

Wiebke K Peitsch

http://www.w3.org/2001/XMLSchema#string

P2860

The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis

Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.

Elicitation and use of patients' preferences in the treatment of psoriasis: a systematic review.

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.

Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities.

Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses.

Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice

Attributable risk estimate of severe psoriasis on major cardiovascular events

Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis.

P304

e0144335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0144335

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26633680

http://www.w3.org/2001/XMLSchema#string

P932

4669171

http://www.w3.org/2001/XMLSchema#string

Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.

about

P2860

P2860

Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932